99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

Condition:   Breast Cancer Intervention:   Drug: 99mTc-HPArk2 Sponsor:   Peking Union Medical College Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions99mTc-HYNIC-H10F specifically accumulates in HER2-positive tumors. Compared with trastuzumab,99mTc-HYNIC-H10F binds to a different domain of HER2 antigen, providing new opportunities to monitor HER2 expression levels before/during/after trastuzumab treatment for more effective personalized treatment.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Condition:   Primary Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   Institute of Bioorganic Chemistry, Russian Academy of Sciences;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, an intermediate (compound 3), which could be hydrolyzed into the ligand (compound L) consisting of palbociclib as the bioactive molecule and 6-hydrazino nicotinamide (HYNIC) as the bifunctional chelator, was synthesized. Compound L was radiolabeled with 99mTc using tricine/TPPTS or tricine/TPPMS as co-ligands. 99mTc-tricine-TPPTS-L and 99mTc-tricine-TPPMS-L were prepared with high radiochemical purity without postlabeling purification. They had great in vitro stability. Both radiotracers were hydrophilic, but 99mTc-tricine-TPPTS-L had a lower log P value. In vitro cell uptake studies in MCF-7 ...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hospitals | Research | SPECT